Abstract
Blister formation in skin and mucous membranes results from a loss of cell-cell or cell-matrix adhesion and is a common outcome of pathological events in a variety of conditions, including autoimmune and genetic diseases, viral and bacterial infections, or injury by physical and chemical factors. Autoantibodies against structural components maintaining cell-cell and cell-matrix adhesion induce tissue damage in autoimmune blistering diseases. Detection of these autoantibodies either tissue-bound or circulating in serum is essential to diagnose the autoimmune nature of disease. Various immunofluorescence methods as well as molecular immunoassays, including enzyme-linked immunosorbent assay and immunoblotting, belong to the modern diagnostic algorithms for these disorders. There is still a considerable need to increase awareness of the rare autoimmune blistering diseases, which often show a severe, chronic-relapsing course, among physicians and the public. This review article describes the immunopathological features of autoimmune bullous diseases and the molecular immunoassays currently available for their diagnosis and monitoring.
Keywords: Autoantibodies, autoantigens, basement membrane, desmosome, ELISA, extracellular matrix, hemidesmosome, immunoassay, immunoblotting, immunofluorescence microscopy.
Current Molecular Medicine
Title:Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Volume: 14 Issue: 1
Author(s): J.V. Otten, T. Hashimoto, M. Hertl, A.S. Payne and C. Sitaru
Affiliation:
Keywords: Autoantibodies, autoantigens, basement membrane, desmosome, ELISA, extracellular matrix, hemidesmosome, immunoassay, immunoblotting, immunofluorescence microscopy.
Abstract: Blister formation in skin and mucous membranes results from a loss of cell-cell or cell-matrix adhesion and is a common outcome of pathological events in a variety of conditions, including autoimmune and genetic diseases, viral and bacterial infections, or injury by physical and chemical factors. Autoantibodies against structural components maintaining cell-cell and cell-matrix adhesion induce tissue damage in autoimmune blistering diseases. Detection of these autoantibodies either tissue-bound or circulating in serum is essential to diagnose the autoimmune nature of disease. Various immunofluorescence methods as well as molecular immunoassays, including enzyme-linked immunosorbent assay and immunoblotting, belong to the modern diagnostic algorithms for these disorders. There is still a considerable need to increase awareness of the rare autoimmune blistering diseases, which often show a severe, chronic-relapsing course, among physicians and the public. This review article describes the immunopathological features of autoimmune bullous diseases and the molecular immunoassays currently available for their diagnosis and monitoring.
Export Options
About this article
Cite this article as:
Otten J.V., Hashimoto T., Hertl M., Payne A.S. and Sitaru C., Molecular Diagnosis in Autoimmune Skin Blistering Conditions, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/15665240113136660079
DOI https://dx.doi.org/10.2174/15665240113136660079 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Central G-Protein Coupled Receptors (GPCR)s as Molecular Targets for the Treatment of Obesity: Assets, Liabilities and Development Status
Current Drug Targets - CNS & Neurological Disorders Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers
Current Radiopharmaceuticals Role of TGF-β in Melanoma
Current Pharmaceutical Biotechnology Mitochondria-Targeting Anticancer Metal Complexes
Current Medicinal Chemistry Vitamin D and Breast Cancer Incidence and Outcome
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up
Current Pharmaceutical Design Diversity of Anticancer and Antimicrobial Compounds from Lichens and Lichen-derived Fungi: A Systematic Review (1985-2017)
Current Organic Chemistry Design of Artificial Immunogens Containing Melanoma-associated T-cell Epitopes
Current Gene Therapy Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine Preparation and Preliminary Evaluation of <sup>68</sup>Ga-Acridine: An Attempt to Study the Potential of Radiolabeled DNA Intercalator as a PET Radiotracer for Tumor Imaging
Anti-Cancer Agents in Medicinal Chemistry Advances in Development of Inhibitors of 17β-Hydroxysteroid Dehydrogenases
Anti-Cancer Agents in Medicinal Chemistry Multiscale Imaging of Nanoparticle Drug Delivery
Current Drug Targets Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer
Current Genomics Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Synthesis and Biological Evaluation of Novel 6-Deoxy-β -D-Psicofuranosyl Mercaptoheterocyclic Compounds
Letters in Drug Design & Discovery A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry